Insurance benefit of Baraclude extended to children over 2

Published: 2016-03-21 14:10:40

Updated: 2016-03-21 14:13:28

A BMS Korea’s hepatitis B treatment, ‘Baraclude’ will be extended in the health insurance benefit to children over 2. Moreover, a Boehringer Ingelheim’s chronic obstructive pulmonary disease(COPD) treatment, ‘Vahelva Respimat’ will be applied for the health insurance.

Recently, the Ministry of Health and Welfare administratively informed the ‘Amendment to Details of the Health Insurance Benef...

Fees

- Email service daily and homepage access.

$300 per month.
5 Email holders per each company.
Anual contract base.